Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017168 (gastroesophageal reflux disease)
 11,783 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The decision for antireflux surgery is often made on an individual basis. How symptom patterns and therapeutic suggestions relate is debatable. There is a long list of differential diagnoses for vomiting not caused by disturbances of the lower esophageal sphincter. Guidelines for the clinical practice in gastroesophageal reflux have been established for children and for adult patients by the Genval Workshop Report and the Trondheim Consensus statement. Endoscopy is indicated if macroscopically visible lesions are to be expected. Routine endoscopic biopsy is not used in the diagnosis of gastroesophageal reflux disease (GERD). pH monitoring is performed in 33 to 77% of patients. If the most prominent symptoms are respiratory, radiographic studies and pH monitoring prove that the symptoms are really related to GERD. Best results with drugs are achieved by effective initial therapy. The effects of long-term treatment are little known. Failed long-term therapy, complications of esophagitis, recurrent aspiration, apnea or "near miss" sudden infant death syndrome, failure to thrive and anatomical abnormalities are indications for surgery. The superiority of laparoscopic antireflux surgery over open surgery depends on the experience of the surgeon. Some surgeons choose a "tailored approach", ie, perform a partial wrap in children with normal peristalsis, an extrashort "floppy" Nissen or a partial wrap for those with impaired peristalsis, and a slightly tighter 360-degree wrap in neurologically impaired children. Partial wraps allow vomiting, which is considered risky in neurologically impaired children.
 ...
PMID:Indications for laparoscopic antireflux procedures in children. 1240 21

Elicitation of the characteristic symptom patterns remains the primary approach to the diagnosis of gastro-oesophageal reflux disease, and this may be enhanced by developments in the use of high-resolution endoscopy and oesophageal biopsy. For future therapy, proton pump inhibitors and anti-reflux surgery may compete with reversible acid pump blockers, reflux inhibitor drugs and diverse luminally delivered physical anti-reflux therapies. Short-segment Barrett's oesophagus is known to be highly prevalent, but its impact on the risk of adenocarcinoma remains poorly defined. Biomarkers for Barrett's oesophagus have been proposed to aid in the stratification of cancer risk, and cytology may assume more importance in the future. Endoscopic surveillance for Barrett's oesophagus is widely practised, but more data are needed to demonstrate cost-effectiveness and a positive impact on mortality. Animal and limited human studies suggest that chemoprevention may become an important strategy in reducing the risk of adenocarcinoma. The ablation of Barrett's epithelium results in a reversal of Barrett's epithelium, albeit with an uncertain long-term outcome.
Best Pract Res Clin Gastroenterol 2002 Dec
PMID:Oesophageal disorders: future developments. 1247 93

Gastro-oesophageal reflux (GOR) is a common phenomenon occurring at any age with a benign prognosis in the majority of cases, but requiring prompt evaluation and treatment when presenting with alarm symptoms or when persisting. Complications of GOR disease (GORD) may be severe. This chapter will discuss the epidemiology, natural course, pathophysiology, clinical presentation, diagnostic and therapeutic approach towards GORD and motility disorders according to different ages. Similarities and differences between infants, children and adults will be highlighted. The superior efficacy and safety of proton pump inhibitors have recently changed the diagnostic and therapeutic recommendations in adults, and possible indications in children are discussed. Only in patients unresponsive to optimal medical treatment are further investigations to exclude other aetiologies for GORD needed (e.g. eosinophilic oesophagitis in infants, scleroderma in adults). Special patient groups such as those with congenital malformations (e.g. oesophageal atresia) are not considered, whereas neurological, respiratory and allergy-affected patients as well as Helicobacter pylori infection are briefly discussed.
Best Pract Res Clin Gastroenterol 2003 Apr
PMID:Gastro-oesophageal reflux disease and motility disorders. 1267 13

Duodenogastric reflux is the retrograde flow of duodenal contents into the stomach that then mix with acid and pepsin. These agents can reflux into the esophagus (ie, duodenogastroesophageal reflux ) and cause gastroesophageal reflux disease (GERD) and its complications, including stricture, Barrett's esophagus, and adenocarcinoma of the esophagus. Medical and surgical treatments of DGER can be difficult. Best medical treatment is proton-pump inhibitors, which decrease DGER by inhibiting both gastric acidity and volume, making less gastric contents available to reflux into the esophagus. The addition of the gamma-aminobutyric (GABA(B)) receptor agonist baclofen may further reduce DGER in patients not responding to proton-pump inhibitors. Bile acid-binding agents (aluminum-containing antacids, cholestyramine, sucralfate, urosodeoxycholic acid) have physiologic rationale, but their efficacy is unproven. Prokinetic agents can reduce DGER and its upper gastrointestinal symptoms by promoting increased gastric emptying. In patients with medically refractory symptoms, a Roux-en-Y diversion or duodenal switch operation may be helpful.
 ...
PMID:Duodenogastric Reflux-induced (Alkaline) Esophagitis. 1472 38

Laparoscopic antireflux surgery is now well established as a treatment of moderate to severe gastro-oesophageal reflux disease. It is indicated for patients with reflux symptoms who have not responded fully to medical therapy or who do not wish to continue medication for the rest of their lives. The evidence base for the determination of appropriate practice has expanded considerably in recent years with the publication of several important randomized trials. These trials have confirmed the superiority of fundoplication compared to medical therapy for the treatment of these patients. They have also demonstrated that the laparoscopic approach achieves an improved short-term outcome compared to the equivalent open approach. Additional trials suggest that the routine application of partial fundoplication procedures achieves equivalent reflux control and fewer side-effects than total fundoplication. Longer-term outcome studies have also been reported recently, with success rates of approximately 90% claimed at 5-8 years. Hence, laparoscopic fundoplication is now the 'gold standard' for the management of patients with more severe gastro-oesophageal reflux disease. New endoscopic treatments for reflux will need to achieve similar outcomes before they can replace the laparoscopic approach.
Best Pract Res Clin Gastroenterol 2004 Feb
PMID:Laparoscopic treatment of gastro-oesophageal reflux disease. 1512 82

We describe the development of endoscopic sewing machines and ancillary equipment for knot tying and thread cutting. We outline the experimental studies in dogs, pigs and baboons prior to the first studies in man. We consider the early results achieved by groups in Europe and the U.S.A., and present the available evidence from peer-reviewed studies and data from numerous abstracts on the use of endoscopic suturing in man for treating gastro-oesophageal reflux. We consider the limitations of the available studies, and outline the requirements for improvements in flexible endoscopic suturing methods.
Best Pract Res Clin Gastroenterol 2004 Feb
PMID:Endoscopic suturing. 1512 83

Enteryx (ethylene vinyl alcohol copolymer) was developed as a bulking agent to be injected endoscopically at the lower oesophageal sphincter (LOS) to increase the competency of the gastro-oesophageal barrier in patients suffering from gastro-oesophageal reflux disease (GORD). Preliminary clinical studies have shown that Enteryx implantation is a fast, minimally invasive and safe procedure. In prospective multicentre studies, significant improvement in reflux symptoms, reduction in the use of proton pump inhibitors (PPIs), and objective improvement in acid oesophageal exposure time were observed after 6 months of follow-up. Improvement of GORD symptoms seems to be correlated with the persistence of the implant. Preliminary data suggest a lengthening and an increase in the LOS relaxation pressure as mechanisms of action of this injection technique. Longer follow-up and controlled sham studies are needed to confirm the efficacy of this technique before it can be proposed as a routine alternative to medical or surgical therapies for GORD.
Best Pract Res Clin Gastroenterol 2004 Feb
PMID:Enteryx. 1512 84

The optimal diagnostic approach to the dyspeptic patient in primary care is still debated. Early endoscopy continues to be the diagnostic gold standard but competing non-invasive strategies challenge this. The most important approaches are empiric antisecretory treatment reserving endoscopy for unresponsive patients and patients with an early symptomatic relapse and helicobacter-based strategies reserving endoscopy for infected patients (test-and-scope) or for failures after eradication therapy (test-and-treat). Early endoscopy is recommended in patients with alarm features and should be considered in patients with new onset dyspepsia after age 50. In the remaining patients, early investigation can only be recommended in areas providing endoscopy at a low cost and with a short waiting list. The test-and-scope strategy may lead to a rise in the referral rates for endoscopy and cannot be recommended. The test-and-treat strategy is well documented in clinical trials as a safe and cost-effective approach. Helicobacter-based strategies are challenged by a decreasing prevalence of peptic ulcer disease and of the infection. In the near future, the empirical acid inhibition strategy will probably be cost-effective as gastro-oesophageal reflux becomes the predominant disorder in dyspeptic patients.
Best Pract Res Clin Gastroenterol 2004 Aug
PMID:Diagnostic approach to dyspepsia. 1532 7

As the incidence of both gastric cancer and peptic ulcer disease have declined, that of gastro-oesophageal reflux disease (GORD) and non-ulcer, or functional dyspepsia (FD) have reached virtually epidemic proportions. As we come to appreciate the expression of these disorders in the community, the real spectrum of each disease has become evident. FD and non-erosive reflux disease (NERD), the most prevalent manifestation of GORD, frequently overlap. Where then does GORD end and FD begin? Is it realistic, or even clinically relevant, to attempt a clear separation between these entities? These are more than issues of mere semantics; therapeutic options may be dictated by the classification of the patient as one or the other. Recent work indicates clearly that NERD is a heterogeneous disorder incorporating some patients who may well harbour subtle manifestations of oesophagitis and others who have entirely normal 24-hour pH studies. These differences may be crucial to the concept of NERD/FD overlap. While evidence in support of this concept is far from complete, it would appear that this overlap is most relevant to those NERD patients who do not exhibit abnormal esophageal acid exposure. These patients truly belong in the spectrum of functional gastrointestinal disorders rather than in GORD; attempts to shoe-horn these individuals into the spectrum of GORD will result in therapeutic disappointment and surgical disaster.
Best Pract Res Clin Gastroenterol 2004 Aug
PMID:Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? 1532 8

Obesity has, among physicians, since long been considered to cause gastro-oesophageal reflux. The evidence in support of this belief has been scarce, however. During the last few years some population-based studies have addressed this clinically important issue. These studies demonstrated a clear and dose-dependent association between increasing degrees of overweight and gastro-oesophageal reflux. The mechanisms by which obesity causes reflux are unknown, although there is some limited data suggesting that hiatal hernia may be the causal link between obesity and reflux. Moreover, some evidence has been presented showing that obesity is clearly a stronger risk factor among women than among men, and that the relation between overweight and reflux is substantially augmented by postmenopausal hormone therapy. The data so far available point in the direction of oestrogens, the activity of which is strengthened by increasing body mass, being responsible for this effect. If the results are repeated in future studies, postmenopausal therapy might be avoided among obese females suffering from severe reflux. Weight-reduction seems to reduce the risk of symptomatic gastro-oesophageal reflux disease, indicating that such strategy might be a useful tool in the treatment of reflux.
Best Pract Res Clin Gastroenterol 2004 Dec
PMID:The relation between body mass and gastro-oesophageal reflux. 1556 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>